ライフサイエンスコーパス: liver metastases

1 lowing 3 months of PTX therapy for recurrent liver metastases.

2 atocellular carcinomas, were also mutated in liver metastases.

3 regressions in primary tumors and colorectal liver metastases.

4 SCs to form a premetastatic niche to promote liver metastases.

5 r (166)Ho radioembolization in patients with liver metastases.

6 lications of radioembolization of colorectal liver metastases.

7 loid cells can be used to target established liver metastases.

8 e of invasive tumors and no apparent lung or liver metastases.

9 to liver endothelial cells and formation of liver metastases.

10 colorectal cancer patient with nonresectable liver metastases.

11 premetastatic niche that ultimately promoted liver metastases.

12 ients with metastatic colorectal cancer with liver metastases.

13 patic peritoneal metastasis and hematogenous liver metastases.

14 e limited response rates in the treatment of liver metastases.

15 vacizumab in patients with colorectal cancer liver metastases.

16 est (90)Y study for patients with colorectal liver metastases.

17 ue of hepatic USG for detecting asymptomatic liver metastases.

18 as reduced in CTC compared to tumor cells in liver metastases.

19 eived (90)Y radioembolization for colorectal liver metastases.

20 PanNETs associated with a different risk for liver metastases.

21 marker for metastatic activity of colorectal liver metastases.

22 glass microsphere treatments for colorectal liver metastases.

23 sed cell death in primary CTCL tumors and in liver metastases.

24 ncer, both CVX-060 and regorafenib inhibited liver metastases.

25 tumors, adjacent normal tissues, and matched liver metastases.

26 ic tumors and to accelerate the formation of liver metastases.

27 h as hepatocellular carcinoma and colorectal liver metastases.

28 dict response to neoadjuvant chemotherapy in liver metastases.

29 and a potential target for interference with liver metastases.

30 between primary colorectal tumors and their liver metastases.

31 t detection of bone lesions, lymph node, and liver metastases.

32 = 0.035) were independently associated with liver metastases.

33 nagement strategies exist for neuroendocrine liver metastases.

34 of two primary CRC tumors and their matched liver metastases.

35 ase recurrence after resection of colorectal liver metastases.

36 n bile ducts induced cholangiocarcinoma with liver metastases.

37 as performed in mice bearing patient-derived liver metastases.

38 eight fresh human colorectal carcinoma (CRC) liver metastases.

39 portantly, ADPh prevented the development of liver metastases.

40 y, for the detection and characterization of liver metastases.

41 patients also had synchronous resections of liver metastases.

42 ents with colorectal cancer with synchronous liver metastases.

43 fibroblasts associated with human colorectal liver metastases.

44 e quality and in the detection of colorectal liver metastases.

45 that obtained after resection of colorectal liver metastases.

46 on 538 to glycine (D538G), was identified in liver metastases.

47 for salvage patients with colorectal cancer liver metastases.

48 (PanNETs) associated with the development of liver metastases.

49 tratified by PD-L1 status, world region, and liver metastases.

50 ut was explicitly related to the presence of liver metastases.

51 at population, and in patients with baseline liver metastases.

52 kinase inhibitors and patients with baseline liver metastases.

53 iable imaging modality that allows to assess liver metastases.

54 positive patients and patients with baseline liver metastases.

55 consisting of patients receiving therapy for liver metastases.

56 of primary liver tumors and melanoma-derived liver metastases.

57 on of prior systemic therapy and presence of liver metastases.

58 ic lineages of two CRC patients with matched liver metastases.

59 alterations in pancreatic primary tumors and liver metastases.

60 le toxicity profile in salvage patients with liver metastases.

61 construction algorithms for the detection of liver metastases.

62 uperior to (177)Lu-PSMA for the treatment of liver metastases (0% vs. 56% progression).

63 et the inclusion criteria: 17 had colorectal liver metastases, 1 had hepatocellular carcinoma, 1 had

64 ersus BCP was seen in patients with baseline liver metastases (13.3 months [11.6-NE] with ABCP [52 of

65 Among patients with colorectal liver metastases (29 before vs 76 after implementation),

66 In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favor

67 with 473 procedures (139 HCC, 198 colorectal liver metastases, 61 neuroendocrine liver metastases, an

68 rlying hepatic diagnoses included colorectal liver metastases (69%), hepatocellular carcinoma (18%),

69 patocellular carcinoma (18%), non-colorectal liver metastases (7%), and intrahepatic cholangiocarcino

70 1), preoperative chemotherapy for colorectal liver metastases (70%, 82%, 89%, P < 0.001) and median o

71 92.4% vs. 69.7% and 89.4%, respectively) and liver metastases (97.3% vs. 92.1% and 94.8%, respectivel

72 give patients with nonresectable colorectal liver metastases a 5-year overall survival comparable to

73 ion is also prevalent in human breast cancer liver metastases, a setting in which results with anti-a

74 ersus nonanatomical resection for colorectal liver metastases, according to KRAS mutational status.

75 requency of resections for colorectal cancer liver metastases across the English NHS.

76 d systemic increases in TIMP1 developed more liver metastases after injections of pancreatic cancer c

77 % of patients with colorectal cancer develop liver metastases after resection of the primary tumor, a

78 ong with the proportion of mice with diffuse liver metastases, an effect ablated by coexpression of N

79 ctable or suboptimally resectable colorectal liver metastases and a WHO performance status of 0-2 wer

80 ighest uptake of FAPI tracer was observed in liver metastases and anal cancer, with an SUV(max) of 9.

81 Volumes of interest were drawn over liver metastases and aorta.

82 Patients with colorectal liver metastases and available KRAS data treated with re

83 increasing evidence to support resection of liver metastases and concurrent EHD in selected patients

84 term survival is possible after resection of liver metastases and concurrent EHD, but true cure is ra

85 MRI detected 489 liver metastases and MDCT 384.

86 We found that human colorectal cancer liver metastases and murine gastrointestinal experimenta

87 ified subgroups, such as those patients with liver metastases and those with no response to prior ant

88 number dramatically during establishment of liver metastases and were recruited from bone marrow by

89 riate analysis, (18)F-FDG PET, G3 tumor, >=2 liver metastases, and >=2 prior therapies were independe

90 ine patients with NETs (41 patients with 162 liver metastases, and 18 control subjects with no liver

91 lorectal liver metastases, 61 neuroendocrine liver metastases, and 75 other) for a total of 875 tumor

92 vs 1), age (<50 vs >/=50 years), presence of liver metastases, and histopathological grade (2 vs 3).

93 in established SCLC primary lung tumors, in liver metastases, and in chemotherapy-resistant tumors.

94 response to neoadjuvant chemotherapy in the liver metastases, and inhibition of this protein at both

95 colorectal liver metastases, neuroendocrine liver metastases, and other cancers.

96 ation was stratified by previous taxane use, liver metastases, and PD-L1 expression on tumour-infiltr

97 Stratification factors were sex, baseline liver metastases, and PD-L1 tumour expression.

98 0.003) after controlling for CTR, number of liver metastases, and preoperative extrahepatic disease.

99 nd found the combination to inhibit lung and liver metastases, and prolong host survival without toxi

100 12 using terms describing colorectal cancer, liver metastases, and surgery.

101 d in purine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases sha

102 ng photothermal ablation (PTA) of colorectal liver metastases, and thus increase ablation zones.

103 Liver metastases are a major cause of death from colorec

104 ses and murine gastrointestinal experimental liver metastases are infiltrated by neutrophils.

105 reason for this unfavorable outcome is that liver metastases are poorly vascularized, limiting the a

106 d immediately after percutaneous ablation of liver metastases are predictors of local treatment failu

107 Current treatments for liver metastases arising from primary breast and lung ca

108 expressing clones formed significantly fewer liver metastases as compared with control clones.

109 CL5-promoter activation within the stroma of liver metastases as evidenced by tumor-selective iodide

110 ur knowledge), robust MRI detection of early liver metastases as small as approximately 0.24 mm in di

111 PKLR expression was increased in liver metastases as well as in primary colorectal tumors

112 ew the existing approaches to neuroendocrine liver metastases, assess the evidence on which managemen

113 tic castration-resistant prostate cancer and liver metastases assigned to (177)Lu-PSMA alone (n = 31)

114 CUP with liver metastases associated with liver (1.44) cancer in

115 excluded because of unequivocal evidence of liver metastases at baseline whole-body MRI, two partici

116 between observers 1 and 2 for characterizing liver metastases at per-lesion analysis (kappa coefficie

117 Two of them had already liver metastases at surgery, 13 were disease-free at las

118 pproximately 75-80% of patients present with liver metastases at the time of their diagnosis, and 20%

119 ategies for patients with bilobar colorectal liver metastases (bCRLM).

120 Most colorectal liver metastases become refractory to chemotherapy and b

121 ected patients with nonresectable colorectal liver metastases benefit from liver transplantation and

122 an initial complete resection of colorectal liver metastases between 1992 and 2012.

123 ulted not only in a higher detection rate of liver metastases but also in a significantly higher lesi

124 lyst for photothermal ablation of colorectal liver metastases by increasing ablation zones.

125 e a metastatic CRC mouse model and show that liver metastases can manifest without a lymph node metas

126 )F-DCFPyL in late stages, when rare cases of liver metastases can occur.

127 In a mouse model of spleen-liver metastases, cancer dissemination to liver was dram

128 ong-term survival to selected patients whose liver metastases cannot be removed in a single procedure

129 n oncological outcomes for colorectal cancer liver metastases (CCLM) remain inconclusive.

130 esection after chemotherapy for colon cancer liver metastases (CCLM).

131 f postoperative complications for colorectal liver metastases (CLM) in the era of RAS mutation analys

132 ve chemotherapy and resection for colorectal liver metastases (CLM).

133 s who had a complete resection of colorectal liver metastases (CLM).

134 ischemia (RLI) after resection of colorectal liver metastases (CLMs) is unknown to date.

135 ) after liver transplantation for colorectal liver metastases (CLMs).

136 56.8 y; range, 35-79 y) for the treatment of liver metastases (colorectal, n = 23; breast, n = 1; and

137 creased levels of AKT2 and resulted in fewer liver metastases compared to controls in vivo.

138 PGE2 had increased numbers of cecal CSCs and liver metastases compared with controls after intracecal

139 survival of patients with colorectal cancer liver metastases (CRC-LM).

140 have developed orthotopic colorectal cancer liver metastases (CRCLM) and primary cholangiocarcinoma

141 ble liver malignancies, including colorectal liver metastases (CRLM) ( 1 ).

142 luate outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic dise

143 KRAS-mutated colorectal liver metastases (CRLM) are known to be more aggressive

144 in the treatment of patients with colorectal liver metastases (CRLM) is the Kirsten rat sarcoma viral

145 y-nine patients with unresectable colorectal liver metastases (CRLM) were included in a single-instit

146 tumors (NET), and colorectal carcinoma with liver metastases (CRLM), but not cholangiocarcinoma (CCA

147 ion after partial hepatectomy for colorectal liver metastases (CRLM).

148 d-line treatment of patients with colorectal liver metastases (CRLM).

149 A total of 141 (70%) patients had colorectal liver metastases (CRLM).

150 ogical outcome after resection of colorectal liver metastases (CRLM).

151 comes to open liver resection for colorectal liver metastases (CRLMs).

152 lorectal cancer (CRC), it is unknown whether liver metastases derive from cancer cells that first col

153 imary SI-NETs from patients with and without liver metastases detected at the time of surgery and ini

154 established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte-media

155 d mediastinal nodes in lung cancer and small liver metastases due to background noise.

156 We found that 80% of clinical liver metastases express a NANOG with 75% of the positiv

157 Importantly, human liver metastases express higher CKB and SLC6A8 levels an

158 ry tumors, lymph node metastases (LNMs), and liver metastases from 10 CRC patients.

159 ssue from both primary colorectal tumour and liver metastases from 17 patients was subjected to prote

160 ho underwent primary resection of colorectal liver metastases from 2 major hepatobiliary units in the

161 rs, a shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in

162 icrosphere radioembolization of unresectable liver metastases from breast cancer.

163 Clinically, immunohistochemical analysis of liver metastases from chemotherapy-naive colon cancer pa

164 rs) who underwent radioembolization to treat liver metastases from colorectal adenocarcinoma between

165 duals with hepatocellular carcinoma (HCC) or liver metastases from colorectal cancer (LM-CRC).

166 pected of having hepatocellular carcinoma or liver metastases from colorectal cancer and were schedul

167 ring preoperative treatment of patients with liver metastases from colorectal cancer, and its predict

168 cle of treatment in patients with resectable liver metastases from colorectal cancer, within a phase

169 This increase in formation of liver metastases from injected pancreatic cancer cells w

170 ve for the detection and characterization of liver metastases from NETs than T2-weighted FSE and dyna

171 unexpectedly caused a remarkable increase in liver metastases from neuroblastoma and breast cancer ce

172 e various treatment options in patients with liver metastases from neuroendocrine tumors.

173 comparison group consisted of patients with liver metastases from non-NET cancer.

174 ished PET response criteria in patients with liver metastases from pancreatic cancer after treatment

175 atic progression after radioembolization for liver metastases from pancreatic cancer.

176 before and 3 mo after radioembolization for liver metastases from pancreatic cancer.

177 or oligometastatic disease (defined as </=3 liver metastases) (group 2).

178 The proteome heterogeneity of human CRC liver metastases has a distinct, organized pattern.

179 ting lymphocytes in primary colon tumors and liver metastases have improved outcomes.

180 5 [0.71-1.03]), or in patients with baseline liver metastases (HR 0.87 [0.57-1.32]).

181 patient affected of irresectable colorectal liver metastases (i-CRLM) BACKGROUND:: A renaissance of

182 athologic findings of core liver biopsies of liver metastases identified by needle localization in a

183 then, she had been treated with resection of liver metastases in 2009 and 2010, palliative combinatio

184 6 to 82 years), hemoglobin < 10 g/dL in 17%, liver metastases in 30%, median time from prior chemothe

185 nes was performed from primary tumors and/or liver metastases in 401 patients undergoing CLM resectio

186 icantly reduced whole body, lung, kidney and liver metastases in an experimental metastases mouse mod

187 4-HAP also reduced liver metastases in human pancreatic cancer-bearing nude

188 otherapy and surgery for operable colorectal liver metastases in KRAS exon 2 wild-type patients resul

189 ase signaling, and promotes the formation of liver metastases in mice.

190 Given the high frequency of liver metastases in neuroendocrine tumor patients, we ai

191 opic and open liver resection for colorectal liver metastases in the elderly.

192 sponses with both regressive and progressive liver metastases in the same patient (best vs. worst res

193 ssociated with CTC shedding from established liver metastases in the training and validation cohorts.

194 (Arp2/3) is required for vessel co-option in liver metastases in vivo and that, in this setting, comb

195 sseminated cancer cells are Lgr5(-) and seed liver metastases in which Lgr5(+) cells then appear, sho

196 ene therapy completely cured established CRC liver metastases in ~50% of mice and provided long-lasti

197 trant metastasis (100% metastasis; with >80% liver metastases) in Kras(G12D)-driven serrated cancer.

198 Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic art

199 hway mutations/chromosomal inversions in 5/5 liver metastases, irrespective of cancer types.

200 Conclusion CT evaluation of colorectal liver metastases is compromised with modest radiation do

201 Early detection of liver metastases is crucial to appropriately select pati

202 er curatively intended surgery of colorectal liver metastases is feasible and may significantly impro

203 ents with colorectal cancer with synchronous liver metastases is possible but is associated with a wi

204 ostic factors after resection for colorectal liver metastases is unclear.

205 ot be withheld from patients with colorectal liver metastases lacking intratumoral (99m)Tc-MAA accumu

206 in already established, experimental, murine liver metastases led to diminished metastatic growth.

207 r curatively intended surgery for colorectal liver metastases, liver recurrences occur in more than 6

208 who underwent liver transplantation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) o

209 udy aimed to assess the prognostic impact of liver metastases (LM) in patients with colorectal perito

210 Liver metastases (LM) remain a major cause of cancer-ass

211 nt for patients with colorectal cancer (CRC) liver metastases (LM).

212 ty, PD-L1 status, and presence or absence of liver metastases, lung metastases, or both.

213 metastases vs as suppressor in prostate and liver metastases) may eventually help us to develop bett

214 -six patients with a total of 435 colorectal liver metastases (mean number of lesions +/- SD, 6.6 +/-

215 Embolization of liver metastases might reduce symptoms of ZES although a

216 t cancer liver metastases, n = 7; colorectal liver metastases, n = 5; hepatocellular carcinoma, n = 8

217 ectable advanced liver tumors (breast cancer liver metastases, n = 7; colorectal liver metastases, n

218 ents with multifocal, bilobar neuroendocrine liver metastases (NELM) after the first transarterial ch

219 : hepatocellular carcinoma (HCC), colorectal liver metastases, neuroendocrine liver metastases, and o

220 cancer (WHO performance status 0 or 1) with liver metastases not suitable for curative resection or

221 ns of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain.

222 Liver metastases occurred in 430 patients; 240 received

223 y mass index: 18.5 kg/m) with neuroendocrine liver metastases of a digestive origin underwent hybrid

224 patients with unresectable, chemorefractory liver metastases of any origin were enrolled in this pha

225 adiation therapy (SIRT) for the treatment of liver metastases of castration-resistant prostate cancer

226 on criteria were Body-Mass index (BMI) > 40, liver metastases of malignant diseases and concurrent or

227 This led to inhibition of growth of liver metastases of multiple tumors regardless of their

228 ly, an analogous myeloid subset was found in liver metastases of some colorectal cancer patients.

229 growing in the liver in vivo and a subset of liver metastases of uveal melanoma patients express acti

230 sequencing identified mutations enriched in liver metastases of various cancers, including Notch pat

231 laparoscopic liver resection, for colorectal liver metastases, offers significant lower morbidity, an

232 colorectal carcinoma undergoing surgery for liver metastases or hepatocellular carcinoma.

233 ls with tumor-conditioned myeloid cells from liver metastases or myeloid cell conditioned media down-

234 nfunctioning pancreatic NET with more than 3 liver metastases or other metastases was 25 mo.

235 t diagnostic tasks, such as the detection of liver metastases or pancreatic masses.

236 ngly used for the treatment of patients with liver metastases or primary liver cancer.

237 with non-small cell lung cancer, colorectal liver metastases, or metastatic melanoma who were scanne

238 th and without prior anti-PD-(L)1 treatment, liver metastases, or upper-tract disease.

239 lizing antibody to mice bearing experimental liver metastases phenocopied neutrophil depletion by red

240 Chemotherapy-naive patients with liver metastases plus or minus limited extrahepatic meta

241 diameter of less than 8 cm for the 2 largest liver metastases predicted time to intrahepatic progress

242 esis, GCLC, becomes overexpressed in patient liver metastases, promotes cell survival under hypoxic a

243 dex, primary tumor location, or treatment of liver metastases, PTR with/without liver treatment impro

244 roups of patients, together with more than 3 liver metastases, R1 resection, and extrahepatic disease

245 ference in OS was also seen in patients with liver metastases randomized to eribulin versus control (

246 o the significantly higher detection rate of liver metastases rather than tumor differentiation grade

247 The majority of patients with liver metastases receive palliative chemotherapy, with a

248 tients with colorectal carcinoma and bilobar liver metastases received whole-liver radioembolization

249 Methods: Twenty-three mCRC patients with liver metastases refractory to chemotherapy were include

250 m study, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and inel

251 s (NETs), but detection rates, especially of liver metastases, remain limited even with PET/CT.

252 Surgery for colorectal liver metastases results in an overall survival of about

253 r "radioembolization" and "colorectal cancer liver metastases." Results were described separately for

254 d in 4/5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including

255 Colorectal liver metastases shed intact tumor cells with an invasiv

256 analyses suggest that surgical resection of liver metastases should be carefully considered in this

257 margin achieved in patients with colorectal liver metastases should now be considered the standard o

258 Pathway analyses of all mutated genes in liver metastases showed aberrant tumor necrosis factor a

259 Radioembolization for breast cancer liver metastases shows encouraging local response rates

260 not granulocytes, isolated from experimental liver metastases stimulated migration and invasion of MC

261 creatic neuroendocrine tumor with multifocal liver metastases, suggesting that excessive overproducti

262 f (18)F-FLT may limit utility for imaging of liver metastases.Targeting angiogenesis has had some suc

263 venous injection of LV12 cells produced more liver metastases than QRsP-11 cells, whereas the inciden

264 We found a marked reduction in liver metastases that correlated with a greatly reduced

265 era of effective chemotherapy for colorectal liver metastases, the association between surgical margi

266 ines of systemic therapy and the presence of liver metastases, to receive intravenous gemcitabine 100

267 f a large cohort of patients with colorectal liver metastases treated with (90)Y radioembolization us

268 microenvironment of either primary tumors or liver metastases triggered regression of established tum

269 Patients with colorectal cancer with liver metastases undergo hepatic resection with curative

270 Fifty-one patients with colorectal liver metastases underwent body CT (thorax and abdomen)

271 atients with pathologically proven mCRC (512 liver metastases) underwent Gd-EOB MRI and MDCT imaging.

272 metastases, and 18 control subjects with no liver metastases) underwent MR imaging that included DW,

273 Progression of liver metastases warranted further therapy and temozolom

274 rom explant cultures of CRC patients-derived liver metastases was associated with response to OXA + C

275 stases, whereas progression of nonresectable liver metastases was observed in the chemotherapy group.

276 low passage cultures from primary tumors and liver metastases we show that ATM loss accelerates Kras-

277 Increased liver metastases were also seen after treatment with the

278 years; range 43.6-66.3), with neuroendocrine liver metastases were analyzed by means of distributed p

279 tratumoral (99m)Tc-MAA uptake was rated, and liver metastases were classified according to changes in

280 A rapid tumor progression was observed: liver metastases were detected after 4 months.

281 distant metastases, although in one patient liver metastases were evident on (18)F-FDG but not on (1

282 gnosed with metastatic disease in 2009, when liver metastases were found 1 year after the primary tre

283 patients treated with liver embolization for liver metastases were found, and similar results were de

284 3 molecular subtypes with differing risks of liver metastases were identified.

285 Unexpectedly, primary tumor volume and liver metastases were increased in 5-LO-KO mice.

286 for OS, and (18)F-FDG PET, G3 tumor, and >=3 liver metastases were independent prognostic factors for

287 ctable or suboptimally resectable colorectal liver metastases were randomised in a 1:1 ratio to recei

288 Patients with resectable colorectal liver metastases were randomly assigned to have open or

289 curative resection of at least 4 colorectal liver metastases, were selected from a prospective datab

290 cells demonstrated significant reduction in liver metastases when treated with N(1)-(3-aminopropyl)-

291 or bone metastases, distant lymph nodes, and liver metastases, whereas CT was more sensitive for lung

292 Food and Drug Administration for colorectal liver metastases, whereas institutional review board app

293 in a syngeneic tumor model resulted in fewer liver metastases, whereas PHD3 knockdown induced tumor s

294 ys containing samples from CRC patients with liver metastases who had undergone hepatic resection.

295 ated the second hepatectomy in patients with liver metastases who required a 2-stage hepatectomy.

296 thods: Patients with primary liver cancer or liver metastases who underwent radioembolization with gl

297 However, colony size was greatly reduced in liver metastases with decreased invasion into adjacent t

298 clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemo

299 ge of the biological phenotype of colorectal liver metastases would be invaluable to inform clinical

300 , chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of prognostic f